Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (91-100 of 263) with videos related to

Pageof 27
Sort By:
Blood|November 1, 2007
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemiaChris Saddler, Peter Ouillette, Lisa Kujawski, et al.
Magnetic Resonance in Medicine|January 24, 2024
Quantitative MRI reveals heterogeneous impacts of treatment on diseased bone marrow in a mouse model of myelofibrosisTanner H Robison, Winston Lee, Kathryn E Luker, et al.
Cancer|December 13, 2005
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyGautam Borthakur, Hagop Kantarjian, George Daley, et al.
Blood|January 5, 2007
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cellsGeoffrey A Bartholomeusz, Moshe Talpaz, Vaibhav Kapuria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2024
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic AlterationsMalathi Kandarpa, Dan Robinson, Yi-Mi Wu, et al.
Cancer|September 26, 2003
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phaseHagop Kantarjian, Susan O'Brien, Jorges Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Jorge Cortes, et al.
Leukemia Research|March 10, 2005
Immune therapy of chronic myelogenous leukemiaRobert Peter Gale, Mary M Horowitz, Moshe Talpaz, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
Blood|April 9, 2004
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosisAlok C Bharti, Shishir Shishodia, James M Reuben, et al.
Pageof 27

Showing results (91-100 of 263) with videos related to

Sort By:
Pageof 27
Blood|November 1, 2007
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemiaChris Saddler, Peter Ouillette, Lisa Kujawski, et al.
Magnetic Resonance in Medicine|January 24, 2024
Quantitative MRI reveals heterogeneous impacts of treatment on diseased bone marrow in a mouse model of myelofibrosisTanner H Robison, Winston Lee, Kathryn E Luker, et al.
Cancer|December 13, 2005
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyGautam Borthakur, Hagop Kantarjian, George Daley, et al.
Blood|January 5, 2007
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cellsGeoffrey A Bartholomeusz, Moshe Talpaz, Vaibhav Kapuria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2024
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic AlterationsMalathi Kandarpa, Dan Robinson, Yi-Mi Wu, et al.
Cancer|September 26, 2003
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phaseHagop Kantarjian, Susan O'Brien, Jorges Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Jorge Cortes, et al.
Leukemia Research|March 10, 2005
Immune therapy of chronic myelogenous leukemiaRobert Peter Gale, Mary M Horowitz, Moshe Talpaz, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
Blood|April 9, 2004
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosisAlok C Bharti, Shishir Shishodia, James M Reuben, et al.
Pageof 27